The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Bruno GuerciFrancesco GiorginoHélène SapinKristina BoyeJérémie LebrecMarco Orsini FedericiElke HeitmannAnne DibMartin FüchtenbuschLuis-Emilio Garcia-PerezPublished in: Diabetes, obesity & metabolism (2022)
In the real-world setting, dulaglutide and liraglutide cohorts achieved good persistence with similarly improved glycaemic control that was accompanied by weight loss at 12 months, consistent with previous clinical trial results.